TG Therapeutics, Inc. (TGTX) Stock
Key stats
- Market cap
- $9.94B
- Price / Earnings ratio
- 91.6x
- EPS (TTM)
- $0.78
- Volume
- Loading
- 52-week high
- $68.03
- 52-week low
- $26.76
Source: third-party data provider, as of November 13, 2026
Compare with TGTX
Recent news
TG Therapeutics’ CEO Sees Global Revenue Exceeding $1B In 2026 – BRIUMVI Drives Q3 Topline Beat
TG Therapeutics’ CEO Sees Global Revenue Exceeding $1B In 2026 – BRIUMVI Drives Q3 Topline Beat
TGTX
Biotech Beats SPY And QQQ In Market Rout — Now Hims Earnings And Summit’s FDA Test Take Center Stage ‘
Biotech Beats SPY And QQQ In Market Rout — Now Hims Earnings And Summit’s FDA Test Take Center Stage ‘
TGTX
TG Therapeutics to Host Conference Call on Third Quarter 2026 Financial Results and Business Update
TG Therapeutics to Host Conference Call on Third Quarter 2026 Financial Results and Business Update
TGTXTGTX Stock Hits Fresh 52-Week High Ahead Of Earnings Amid Buyout Buzz
TGTX Stock Hits Fresh 52-Week High Ahead Of Earnings Amid Buyout Buzz
TGTXNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 69.78
- MACD 12/26/9
- 2.34
- EMA 9 of MACD
- 1.52
- MACD histogram
- 0.81
- SMA 50
- $56.39
- Price above SMA 50
- EMA 50
- $56.63
- Price above EMA 50
- SMA 200
- $45.03
- Price above SMA 200
- EMA 200
- $45.74
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.45 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
TG Therapeutics’ CEO Sees Global Revenue Exceeding $1B In 2026 – BRIUMVI Drives Q3 Topline Beat
TG Therapeutics’ CEO Sees Global Revenue Exceeding $1B In 2026 – BRIUMVI Drives Q3 Topline Beat
TGTXBiotech Beats SPY And QQQ In Market Rout — Now Hims Earnings And Summit’s FDA Test Take Center Stage ‘
Biotech Beats SPY And QQQ In Market Rout — Now Hims Earnings And Summit’s FDA Test Take Center Stage ‘
TGTXTG Therapeutics to Host Conference Call on Third Quarter 2026 Financial Results and Business Update
TG Therapeutics to Host Conference Call on Third Quarter 2026 Financial Results and Business Update
TGTXTGTX Stock Hits Fresh 52-Week High Ahead Of Earnings Amid Buyout Buzz
TGTX Stock Hits Fresh 52-Week High Ahead Of Earnings Amid Buyout Buzz
TGTX
GRAIL Q3 Earnings Ahead: Galleri Test Adoption to Drive Growth
GRAIL Q3 Earnings Ahead: Galleri Test Adoption to Drive Growth
TGTX
TG Therapeutics (TGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
TG Therapeutics (TGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
TGTXTGTX Stock Bucks Broader Biotech Selloff As Multiple Sclerosis Therapy Shows Promising Early Results — Here’s What Investors Need To Know
TGTX Stock Bucks Broader Biotech Selloff As Multiple Sclerosis Therapy Shows Promising Early Results — Here’s What Investors Need To Know
TGTX
TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026
TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026
TGTX
TG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026
TG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026
TGTX
Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In
Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In
TGTXNews tone: automated (AI) classification of the article's content, not a price prediction.
About TG Therapeutics, Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael S. Weiss Esq., J.D. | Chairman, CEO & President | 1966 |
| Mr. Sean A. Power CPA | CFO, Corporate Secretary & Treasurer | 1982 |
| Ms. Jenna Bosco | Senior Vice President of Corporate Communications | — |
| Mr. Adam Waldman | Chief Commercialization Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 69.78
- MACD 12/26/9
- 2.34
- EMA 9 of MACD
- 1.52
- MACD histogram
- 0.81
- SMA 50
- $56.39
- Price above SMA 50
- EMA 50
- $56.63
- Price above EMA 50
- SMA 200
- $45.03
- Price above SMA 200
- EMA 200
- $45.74
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $71.00
- Average
- $74.50
- High
- $78.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -43.8 | +21.1 | ||||||||||
| 2022 | -43.4 | -16.1 | -7.6 | -31.2 | -41.5 | +8.7 | +31.1 | +28.7 | -19.6 | -3.0 | +40.4 | +47.5 |
| 2023 | +31.6 | -4.5 | -1.8 | +49.8 | -13.1 | -9.4 | -9.1 | -0.2 | -21.2 | -5.3 | +26.6 | +23.5 |
| 2024 | -4.7 | +2.0 | -15.3 | -7.5 | +2.6 | +8.9 | +8.9 | +24.1 | +3.4 | +9.8 | +29.4 | -14.2 |
| 2025 | +2.1 | -4.4 | +14.6 | +20.6 | -22.6 | +0.7 | +0.3 | -16.2 | +21.5 | -4.9 | -1.3 | -5.9 |
| 2026 | +0.5 | +3.1 | +13.0 | +0.6 | +12.1 | +46.9 | -2.8 | +17.6 | -0.6 | +14.1 | +9.7 |
